Clinical trials: Spike Protein IgG Antibody
COVID-19 Booster, Spike Protein IgG Antibody
Profiling Spike Protein Antibody Response Post COVID-19 Booster
A descriptive study that will quantify the mean IgG antibodies remaining in vaccinated healthy participants after their COVID booster.
- Trial name
- NCT05476822
- Testing
- Obtain antibody titers
- Volunteers
- healthy volunteers welcome
- Sponsor
- David Grant U.S. Air Force Medical Center
Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
- Trial name
- NCT05654506
- Testing
- Daratumumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
COVID-19 Vaccine, Safety Issues
ChulaCov19 Vaccine in Healthy Adults
This study will be conducted in 2 phases. Phase 1 of this study will be a single-centre, open label, dose escalation first in human (FIH) study conducted in 2 groups of healthy participants.
- Trial name
- NCT04566276
- Testing
- ChulaCov19 vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association